post

Myeloma UK announces new CEO

Press release // 20th June 2017

An experienced and accomplished healthcare leader has been appointed Chief Executive of Myeloma UK.

Rosemarie Finley is joining Myeloma UK from the Epilepsy Society, where she was Acting Chief Executive and Chief Operating Officer.

She has more than 30 years of management experience in the healthcare sector. A trained nurse, she held a number of senior leadership positions at Buckinghamshire Healthcare NHS Trust, including Director of Education, Research and Development; Associate Chief Nurse, Specialist Services Division; Safeguarding Lead, Acute and Community Services and Associate Director of Operations.

Rosemarie has an MBA in Health Management from City University Business School and has also worked as a strategic adviser to a number of pharmaceutical companies.

Myeloma UK is the only organisation in the UK dealing exclusively with myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Its focus is on unlocking the potential for the development and delivery of new treatments, through primary research, strategic partnerships, education and campaigning.

Announcing Rosemarie’s appointment, Judy Dewinter, Chairman of Myeloma UK, said, “I am delighted that Rosemarie is joining us as Chief Executive. She comes to us with a wealth of experience and a track record of strong leadership.

I am delighted that Rosemarie is joining us as Chief Executive. She comes to us with a wealth of experience and a track record of strong leadership.

Judy Dewinter, Chairman of Myeloma UK

“Rosemarie combines her strong commitment to patients and the health and research agenda, with a clear understanding of the healthcare system and how to operate effectively within it. This is absolutely central to our work. The whole team looks forward to working with Rosemarie, as Myeloma UK enters a new and exciting phase in its journey.”

Commenting on her appointment, Rosemarie Finley added, “It is a privilege to be joining Myeloma UK, an organisation with a distinct reputation for putting patients at the heart of its strategy and for working collaboratively. I am looking forward to bringing my expertise of operating in highly complex healthcare environments to drive the organisation forward. Our aim will continue to be the acceleration of improved care, effective treatments and ultimately a cure for myeloma.”

Rosemarie will join Myeloma UK on 28 June 2017.

Notes to editors

About Myeloma UK

Myeloma UK is the only organisation in the UK dealing exclusively with myeloma – our ultimate goal is to find a cure.

We are dedicated to ensuring that patients get access to the right treatment at the right time, and to improving standards of treatment and care through research, education and awareness raising.

Our organisation also provides a range of information and support services to patients, family and friends to help deal with a diagnosis of myeloma.

Myeloma UK receives no Government funding and relies almost entirely on voluntary donations and fundraising.

About myeloma

Myeloma is incurable but treatable blood cancer originating in the bone marrow.

The facts

  • Every year, around 5,500 people in the UK are diagnosed with myeloma
  • On average, 15 people are diagnosed with myeloma every day in the UK
  • Myeloma is a very individual cancer – no two myeloma patients are the same
  • Myeloma has been identified as having one of the highest rates of delay in diagnosis
  • 74% of people diagnosed with myeloma are aged 65 years and over